Neurol. praxi. 2023;24(6):449-452 | DOI: 10.36290/neu.2023.072

A multidisciplinary approach to cognitive deficit in patients with multiple sclerosis

MUDr. Iva Šrotová, Ph.D.1, 2, MUDr. Martina Petrášová1, 2, MUDr. Sabina Flašarová1, PhDr. Radka Michalčáková Neužilová, Ph.D.3, 4, MUDr. Pavla Hanzlíková, Ph.D., MBA5
1 Neurologická klinika Fakultní nemocnice Brno Bohunice
2 Lékařská fakulta Masarykovy univerzity, Brno
3 Fakulta sociálních studií - Katedra psychologie Masarykovy univerzity, Brno
4 Oddělení klinické psychologie Fakultní nemocnice Brno Bohunice
5 Ústav radiodiagnostický Fakultní nemocnice Ostrava a Lékařské fakulty Ostravské Univerzity

Multiple sclerosis (MS) is an immune-based neurodegenerative disease that often leads to cognitive deficit in addition to other symptoms. The decline in cognitive functions has a various prevalence in the respective forms of MS, whereas it occurs more often in progressive variants, however, it always reduces the patient's quality of life. Cognition in patients with MS should be examined as a part of the routine follow-up and coincident diseases, such as depression or anxiety, which can further impair the patient's cognitive abilities, should be also addressed adequately.

Keywords: multiple sclerosis, cognitive deficit, depression, anxiety, SDMT, cognitive processing speed.

Received: November 21, 2023; Revised: November 21, 2023; Accepted: November 21, 2023; Prepublished online: November 21, 2023; Published: December 7, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šrotová I, Petrášová M, Flašarová S, Michalčáková Neužilová R, Hanzlíková P. A multidisciplinary approach to cognitive deficit in patients with multiple sclerosis. Neurol. praxi. 2023;24(6):449-452. doi: 10.36290/neu.2023.072.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ampapa R. Kognitivní dysfunkce u sekundárně progresivní roztroušené sklerózy. Neurol. praxi. 2022;23(3):221-226. doi: 10.36290/neu.2021.094. Go to original source...
    2. Beckmann YY, Gelal F, Eren Ş, et al. Diagnostics to Look beyond the Normal Appearing Brain Tissue (NABT)? A Neuroimaging Study of Patients with Primary Headache and NABT Using Magnetization Transfer Imaging and Diffusion Magnetic Resonance. Clin. Neuroradiol. 2013;23(4):277-283. doi: 10.1007/s00062-013-0203-4. Go to original source... Go to PubMed...
    3. Behrangi N, Fischbach F, Kipp M. Mechanism of Siponimod: Anti­‑Inflammatory and Neuroprotective Mode of Action. Cells. 2019;8(1):24. doi: 10.3390/cells8010024. Go to original source... Go to PubMed...
    4. Benedict RHB, Amato MP, DeLuca J, et al. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol. 2020;19(10):860-871. doi: 10.1016/S1474-4422(20)30277-5. Go to original source... Go to PubMed...
    5. Benedict RHB, DeLuca J, Phillips G, et al. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23:721-733. doi: 10.1177/1352458517690821. Go to original source... Go to PubMed...
    6. Benedict RHB, Penner IK, Kappos L, et al. Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 EXPAND study (2275). Neurology. 2021a;96(15 Supplement)2275. Go to original source...
    7. Benedict RHB, Tomic D, Cree BA, et al. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses. Neurology. 2021 b;96(3):e376-e386. doi: 10.1212/WNL.0000000000011275. Go to original source... Go to PubMed...
    8. Cavedo E, Tran P, Thoprakarn U, et al. Validation of an automatic tool for the rapid measurement of brain atrophy and white matter hyperintensity: QyScore®. Eur. Radiol. 2022;32(5):2949-2961. doi: 10.1007/s00330-021-08385-9. Go to original source... Go to PubMed...
    9. Grzegorski T, Losy J. Cognitive impairment in multiple sclerosis - a review of current knowledge and recent research. Rev Neurosci. 2017;28(8):845-860. doi: 10.1515/revneuro-2017-0011. Go to original source... Go to PubMed...
    10. Hynčicová E., Meluzímová E., Laczó J. Kognice a roztroušená skleróza. Neurol. praxi. 2017;18(6):394-398. doi: 10.36290/neu.2018.055. Go to original source...
    11. Kappos L, Bar­‑Or A, Cree BAC, et al. EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double­‑blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Go to original source... Go to PubMed...
    12. Leavitt VM, Brandstadter R, Fabian M, et al. Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis. Mult Scler. 2020;26(10):1247-1255. doi:10.1177/1352458519860319. Go to original source... Go to PubMed...
    13. Linnhoff S, Fiene M, Heinze HJ, et al. Cognitive Fatigue in Multiple Sclerosis: An Objective Approach to Diagnosis and Treatment by Transcranial Electrical Stimulation. Brain Sci. 2019;9(5):100. doi: 10.3390/brainsci9050100. Go to original source... Go to PubMed...
    14. Papathanasiou A, Messinis L, Georgiou VL, et al. Cognitive impairment in relapsing remitting and secondary progressive multiple sclerosis patients: efficacy of a computerized cognitive screening battery. ISRN Neurol. 2014;2014:151379. doi: 10.1155/2014/151379. Go to original source... Go to PubMed...
    15. Patten SB, Ruth AM, Mauro GC. Depression in multiple sclerosis. Int Rev Psychiatry. 2017;29(5):463-472. doi: 10.1080/09540261.2017.1322555. Go to original source... Go to PubMed...
    16. Petracca M, Saiote C, Bender H, et al. Synchronization and variability imbalance underlie cognitive impairment in primary­‑progressive multiple sclerosis. Sci Rep. 2017;7:46411. doi: 10.1038/srep46411. Go to original source... Go to PubMed...
    17. Pitteri M, Romualdi C, Magliozzi R, et al. Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study. Mult Scler. 2017;23(6):848-854. doi: 10.1177/1352458516665496. Go to original source... Go to PubMed...
    18. Popescu V, Klaver R, Voorn P, et al. What drives MRI­‑measured cortical atrophy in multiple sclerosis? Mult. Scler. J. 2015;21(10):1280-1290. doi: 10.1177/1352458514562440. Go to original source... Go to PubMed...
    19. Rocca MA, Amato MP, De Stefano N, et al. MAGNIMS Study Group. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol. 2015;14(3):302-17. doi: 10.1016/S1474. Go to original source...
    20. Sandroff BM, Schwartz CE, DeLuca J. Measurement and maintenance of reserve in multiple sclerosis. J Neurol. 2016; 263(11):2158-2169. doi: 10.1007/s00415-016-8104-5. Go to original source... Go to PubMed...
    21. Schependom VJ, Nagels G. Targeting Cognitive Impairment in Multiple Sclerosis - The Road toward an Imaging­‑based Biomarker. Front. Neurosci. 2017;11. doi: 10.3389/fnins.2017.00380. Go to original source... Go to PubMed...
    22. Stern Y. Cognitive reserve. Neuropsychologia. 2009;47(10):2015-2028. doi: 10.1016/ j.neuropsychologia.2009. 03. 004. Go to original source...
    23. Strádalová P, Štourač P, Králíčková Nekvapilová E. Ochranné faktory kognitivního deficitu u roztroušené sklerózy. Cesk Slov Neurol N. 2018;81(1):24-28. doi: 10.14735/amcsnn201824. Go to original source...
    24. Sumowski JF. Cognitive reserve as a useful concept for early intervention research in multiple sclerosis. Front. Neurol. 2015;6:176. doi: 10.3389/fneur.2015.00176. Go to original source... Go to PubMed...
    25. Sumowski JF, Rocca MA, Leavitt VM, et al. Brain reserve against physical disability progression over 5 years in multiple sclerosis. Neurology. 2016;86(21):2006-2009. doi:10.1212/WNL.0000000000002702. Go to original source... Go to PubMed...
    26. Sumowski JF, Rocca MA, Leavitt VM, et al. Brain reserve and cognitive reserve in multiple sclerosis: what you've got and how you use it. Neurology. 2013;80(24):2186-2193. doi: 10.1212/WNL.0b013e318296e98b. Go to original source... Go to PubMed...
    27. Sumowski JF, Rocca MA, Leavitt VM et al. Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. Neurology. 2014;82(20):1776-1783. doi: 10.1212/WNL.0000000000000433. Go to original source... Go to PubMed...
    28. Vaněčková M, Seidl Z, Krásenský J, et al. Naše zkušenosti s MR monitorováním pacientů s roztroušenou sklerózou v klinické praxi. Cesk Slov Neurol N. 2010;73/106(6):716-720.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.